Dataset from A Randomised, Double-blind, Placebo-controlled, Parallel Group, 8-week Treatment Study to Investigate the Safety, Pharmacodynamics, and Effect of the TLR7 Agonist, GSK2245035, on the Allergen-induced Asthmatic Response in Subjects With Mild Allergic Asthma

This study will assess whether Toll like receptor 7 (TLR7)-mediated pharmacology, with
intranasal (i.n.) GSK2245035 20 nanogram (ng) administered weekly for a period of 8 weeks,
will lead to reduced allergic reactivity in the lower airways in subjects with mild allergic
asthma.

This will be a randomised, double-blind (sponsor open), placebo-controlled, parallel group,
8-week treatment study.

The study will consist of a screening period of up to approximately 4 weeks (involving two
screening visits), a blinded treatment period of 8 weeks, followed by a follow-up period of
up to 3 months. The total duration of the study for each subject will therefore be a maximum
of approximately 6 months.